Form 4: Actuate Therapeutics CEO Daniel Schmitt Reports Acquisition of Restricted Stock Units Following IPO
SEC Form 4 Filing
Daniel Schmitt, CEO of Actuate Therapeutics, reports the acquisition of 544,111 restricted stock units following the company's initial public offering.
Summary
- Daniel M. Schmitt, the President, CEO, and Director of Actuate Therapeutics, reported a transaction on August 14, 2024.
- Following the company's initial public offering, Schmitt acquired 544,111 restricted stock units.
- 50% of these units vest on the first anniversary of the IPO closing, and the remaining 50% vest on the second anniversary.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing. The grant of restricted stock units is generally viewed positively as it aligns management's interests with shareholders.
Positives
- The grant of restricted stock units to the CEO aligns his interests with the long-term success of the company following its IPO.
Future Outlook
The vesting schedule of the restricted stock units (50% after one year, 50% after two years) suggests a focus on long-term performance and retention of the CEO.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- Shareholders may view the grant of restricted stock units to the CEO as a positive sign, aligning his interests with the company's long-term performance.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of transaction: Grant of restricted stock units to Daniel Schmitt upon closing of the initial public offering. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.